

**IN THE CLAIMS:**

Please delete claims 1 through 10 and add new claims 11 through 20 as follows:

~~11.~~ Use of the R-enantiomers of arylpropionic acids or their derivatives for the preparation of medicaments which inhibit the NF- $\kappa$ B activation cascade and therefore are suited to the treatment of diseases which may be influenced therapeutically beneficial by the inhibition of NF- $\kappa$ B production.

12. Use according to claim 11, wherein the medicament contains the R-arylpropionic acid in an amount of 50 to 1000 mg/dose.

13. Use according to claim 11, wherein the R-arylpropionic acid or R-arylpropionic acid derivative is essentially free of S-arylpropionic acids or S-arylpropionic acid derivatives.

14. Use according to claim 11, wherein the R-arylpropionic acids are selected from those not metabolising to CoA thioesters, and especially are selected from R-flurbiprofen, R-ketoprofen, R-naproxen, R-tiaprofenic acid, and/or R-fenoprofen.

15. Use according to claim 11, wherein the active material is present as alkali metal, alkaline earth metal, ammonium, amino acid salt, preferably as lysinate, megluminate, trometamine, arginate or aluminium salt.

16. Use according to claim 11, wherein the medicament contains usual adjuvants and carrier materials.

17. Use according to claim 11, wherein the medicaments are produced in the form of tablets, dragees or other orally usable forms.

18. Use according to claim 11, wherein the active materials are used in rapidly inflowing, retardedly inflowing or combined in rapidly and retardedly inflowing form.